Primary Hepatocytes for ADME Studies: A Practical Guide

Primary hepatocytes for ADME studies are presented in the MileCell product brochure as in vitro tools for drug development, hepatic metabolism, uptake, transport, hepatotoxicity, and hepatobiliary research. The brochure describes two main product formats - suspension hepatocytes and plateable hepatocytes - along with metabolism, induction, transporter, 3D spheroid, and ASGPR qualification options.

Choosing a format begins with the experimental endpoint. A suspended-cell workflow emphasizes metabolic activity, metabolic stability, and uptake. An attachment-dependent workflow can incorporate monolayer culture, sandwich culture, bile canaliculi assessment, spheroid formation, or ASGPR-related characterization. Species, strain, donor configuration, cell specification, and lot-specific functional evidence are also part of the selection process.

This practical guide reorganizes the brochure content into a clear selection framework. All product claims, experimental conditions, figures, numerical values, and certifications in this article are drawn exclusively from the MileCell Primary Hepatocytes product brochure.

What Are Primary Hepatocytes for ADME Studies?

The brochure positions primary hepatocytes as cellular models that support drug development and hepatotoxicity testing. MileCell attributes product quality to optimized tissue harvesting protocols, enhanced cell isolation techniques, and post-thaw functional characterization intended to support viability, purity, structural integrity, and reliable in vitro performance.

The portfolio is organized around two practical formats. Suspension hepatocytes are described for drug metabolism and uptake studies. Plateable hepatocytes are described for monolayer, sandwich-culture, and spheroid applications involving hepatotoxicity, drug transport, hepatitis virus infection research, hepatic drug metabolism, and hepatobiliary excretion.

Why Model Selection Matters in ADME Studies

The brochure presents different qualification pathways because one hepatocyte format does not address every experimental endpoint in the same way. Metabolism-qualified suspension hepatocytes provide enzyme and stability characterization in a suspended-cell system. Plateable products add morphology, attachment, transporter, 3D spheroid, and ASGPR-related options. Selecting a product therefore requires alignment between the assay question and the available functional evidence.

Quick Reference: Selecting a Hepatocyte Format

How Primary Hepatocytes Support ADME Workflows

1. Suspension Hepatocytes for Drug Metabolism

The brochure describes suspension hepatocyte cultures as an in vitro model for drug metabolism studies. Before batch release, cryopreserved suspension hepatocytes undergo quality control and functional characterization. Listed features include high post-thaw viability, characterization of key CYP, SULT, and UGT enzymes, large batch sizes intended to minimize lot-to-lot variation, broad species coverage, well-stocked inventory, and customizable options.

2. Phase I and Phase II Enzyme Characterization

The CD-1 mouse suspension hepatocyte example includes Phase I activity for CYP1A, CYP3A, CYP2B, and CYP2C readouts and Phase II activity for UGT, ST, and UGT1A1 readouts. The chart identifies phenacetin, testosterone, midazolam, bupropion, S-mephenytoin, 7-hydroxycoumarin, and beta-estradiol as the corresponding substrates shown in the brochure.

3. Plateable Hepatocytes for Attachment-Dependent Culture

Plateable hepatocyte cultures are presented in monolayer, sandwich-culture, and spheroid formats. The brochure lists high post-thaw viability, morphological integrity, attachment efficiency, individual and pooled donor lots, broad species coverage, inventory availability, customizable options, and functional validation that can include transporter, 3D spheroid, and ASGPR qualification.

4. Sandwich Culture for Transporter and Hepatobiliary Studies

The brochure explains that sandwich culture is created by coating the hepatocyte monolayer with collagen I or Matrigel on both sides. This promotes re-establishment of cellular polarity and formation of bile canaliculi-like networks. The resulting model is presented for biliary efflux and uptake transporter studies, prolonged hepatic metabolism, drug-drug interactions, and mechanisms of chronic drug-induced liver injury.

5. 3D Spheroid Qualification

Three-dimensional culture is described as maintaining hepatocyte viability while preserving physiologically relevant phenotypes, gene expression, and protein profiles. Compared with traditional monolayer culture systems, the brochure states that spheroid models require fewer cells, offer greater technical simplicity, and can be adapted for high-throughput applications.

6. ASGPR Qualification for GalNAc-Related Workflows

The brochure presents N-acetylgalactosamine (GalNAc) conjugates as a targeted delivery approach that binds the asialoglycoprotein receptor (ASGPR). GalNAc is described as a highly specific ligand for ASGPR, which is predominantly expressed on the surface of hepatocytes. ASGPR-qualified plateable hepatocytes are therefore included as a distinct qualification option in the portfolio.

Experimental and Performance Data from the Product Brochure

Metabolic Activity

CD-1 mouse suspension hepatocytes were thawed and incubated at 37°C at a cell concentration of 0.5 × 10⁶ cells/mL. Metabolic activities were measured by LC-MS/MS and recorded as pmol/min/10⁶ cells. The figure contains Phase I and Phase II enzyme activity data for lots CD-1477, CD-1488, CD-1499, CD-1500, and CD-1511. The brochure states that the results demonstrate consistently replicable metabolic activity among different lots.

Figure 1. Phase I and Phase II metabolic activity in five CD-1 mouse suspension hepatocyte lots. Cells were incubated at 37°C at 0.5 × 10⁶ cells/mL; activity was measured by LC-MS/MS and reported as pmol/min/10⁶ cells.

Metabolic Stability

The metabolic stabilities of 7-hydroxycoumarin and verapamil were evaluated in CD-1 mouse suspension hepatocytes. Each substrate is shown at 1 µM. Following incubation of thawed cells with the substrate, samples were collected at multiple time points through 120 minutes and analyzed by LC-MS/MS. The plots report the percentage of substrate remaining over incubation time.

Figure 2. Metabolic stability of 1 µM 7-hydroxycoumarin and 1 µM verapamil in CD-1 mouse suspension hepatocytes, with samples analyzed by LC-MS/MS through 120 minutes.

Transporter Qualification in Sandwich Culture

The SD rat plateable hepatocyte example shows 100% confluency and bile canaliculi formation on day 3. The paired fluorescent image shows CDFDA uptake into bile canaliculi. These images support the brochure section describing sandwich culture as a model for biliary efflux and uptake transporters.

Figure 3. SD rat plateable hepatocytes in sandwich culture demonstrate 100% confluency and bile canaliculi formation on day 3 (A), with CDFDA uptake into bile canaliculi (B).

3D Spheroid Formation in Cynomolgus Monkey Hepatocytes

The brochure shows spheroid formation over days 4, 6, 7, and 8 using cynomolgus monkey hepatocytes. The culture was initiated with 3,000 cells. After 8 days, the spheroids reached an approximate diameter of 250-300 µm.

Figure 4. Cynomolgus monkey hepatocyte spheroid formation using 3,000 cells. After 8 days of culture, the spheroids were approximately 250-300 µm in diameter.

ASGPR Expression After Post-Recovery Culture

The brochure presents phase-contrast and fluorescent images of cynomolgus monkey plateable hepatocytes after 4 hours and 12 hours of post-recovery culture. It reports that ASGPR expression decreased with extended culture time.

Figure 5. Phase-contrast and fluorescent images of cynomolgus monkey plateable hepatocytes after 4 hours (A and B) and 12 hours (C and D) of post-recovery culture. The brochure reports that ASGPR expression decreased with extended culture.

Practical Considerations for Selecting Primary Hepatocytes

1. Define the endpoint. Identify whether the study centers on metabolic activity, metabolic stability, uptake, transporter function, hepatobiliary excretion, drug-drug interactions, hepatotoxicity, 3D culture, or ASGPR-related delivery.

2. Choose the format. Use suspension hepatocytes for suspended-cell metabolism and uptake workflows, or plateable hepatocytes when attachment, morphology, sandwich culture, transporter readouts, spheroids, or ASGPR qualification are required.

3. Select the biological configuration. Review species, strain, gender, pooled versus single donors, and cell specification as listed in the brochure.

4. Match the qualification. Confirm metabolism, induction, transporter, 3D spheroid, or ASGPR qualification based on the planned assay.

5. Review lot-specific evidence. Examine the post-thaw, enzyme, attachment, morphology, transporter, spheroid, or receptor-related data relevant to the experiment.

6. Confirm logistics. Verify pack size, batch size, inventory status, and customization requirements before scheduling the study.

Suspension and Plateable Formats at a Glance

Species and Configuration Options

The brochure includes human hepatocytes in the overall availability overview and provides detailed animal portfolio entries. The catalog entries shown use a 5 million-cell size. Suspension products are presented as pooled and metabolism qualified. Plateable entries include pooled or single-donor configurations depending on the species and product entry.

MileCell Primary Hepatocytes

MileCell provides suspension and plateable hepatocyte solutions with broad species coverage and flexible options for gender, pooled or single donors, pack size, batch size, and cell specifications. The brochure lists metabolism, induction, transporter, 3D spheroid, and ASGPR qualification pathways and displays ISO 9001, ISO 14001, and ISO 45001 certifications.

· Suspension hepatocytes with post-thaw quality control and functional characterization for metabolism workflows.

· Plateable hepatocytes for monolayer, sandwich-culture, and spheroid applications.

· Qualification options including metabolism, induction, transporter, 3D spheroid, and ASGPR.

· Species and configuration flexibility, including pooled and selected single-donor entries in the product portfolio.

FAQ: Primary Hepatocytes for ADME Studies

What is the main difference between suspension and plateable hepatocytes?

The brochure positions suspension hepatocytes for drug metabolism studies. Plateable hepatocytes support attachment-dependent formats such as monolayer, sandwich culture, and spheroids, including transporter, hepatotoxicity, hepatic metabolism, and hepatobiliary applications.

Which enzyme systems are characterized in suspension hepatocytes?

The brochure states that key CYP, SULT, and UGT enzymes are characterized. Figure 1 shows CYP1A, CYP3A, CYP2B, CYP2C, UGT, ST, and UGT1A1 activity readouts with the substrates identified in the chart.

What does transporter qualification demonstrate?

The SD rat plateable hepatocyte example shows 100% confluency and bile canaliculi formation on day 3, together with CDFDA uptake into bile canaliculi.

What numerical data are provided for 3D spheroid qualification?

The brochure shows cynomolgus monkey hepatocytes cultured from 3,000 cells. After 8 days, the spheroids were approximately 250-300 µm in diameter.

What does the ASGPR qualification figure show?

The brochure presents phase-contrast and fluorescent images after 4 and 12 hours of post-recovery culture and reports that ASGPR expression decreased as culture time increased.

Can MileCell hepatocyte products be customized?

The brochure lists customizable options including gender, species, pack size, batch size, and cell specifications, and it notes pooled or single-donor availability depending on the product entry.

Conclusion

A practical strategy for selecting primary hepatocytes for ADME studies begins with the assay endpoint. Suspension hepatocytes provide metabolism- and uptake-oriented workflows supported by enzyme activity and metabolic stability characterization. Plateable hepatocytes add attachment-dependent culture, bile canaliculi and transporter assessment, spheroid formation, and ASGPR qualification.

Species, strain, donor configuration, qualification type, and lot-specific functional evidence should then be aligned with the study design. The MileCell brochure provides a portfolio framework spanning suspension and plateable products, multiple animal species and strains, human availability, flexible configurations, and five qualification categories.

Looking for primary hepatocytes for ADME studies? Explore MileCell Primary Hepatocytes, request product information or lot-specific data, or contact the MileCell team for availability and technical support.

Info@milecell-bio.com  |  www.milecell-bio.com